Skip to main content
    E

    Exelixis Inc (EXEL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $69.57
    +0.86 (+1.25%)

    Market Cap: $16.77B

    Last updated: Nov 06, 2026 at 4:27 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +89.16%
    Streak
    10 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$1.22
    Range$0.96 - $1.41
    8 analysts
    Revenue Consensus
    $665M
    Range$641M - $697M
    14 analysts
    Period ending Mar 31, 2027
    EPS Consensus$0.90
    Range$0.86 - $0.94
    2 analysts
    EPS Revisions
    3
    0
    7d
    3
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.94-4.2%
    60d ago$0.97-7.2%
    30d ago$0.94-4.3%
    7d ago$0.94-4.3%
    Current$0.90
    Revenue Consensus
    $699M
    Range$670M - $722M
    4 analysts
    Last 12 of 40 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Mar 27EST
    		-$0.90$0.86 - $0.94--2
    3
    1
    30d
    		-
    Dec 26EST
    		-$1.22$0.96 - $1.41--8--
    Sep 26
    Reported Oct 29
    		$0.85$0.79$0.70 - $0.86+7.59%Beat10
    1
    2
    30d
    		+9.0%
    Jun 26
    Reported Aug 5
    		$0.82$0.75$0.66 - $0.81+9.33%Beat11
    2
    0
    30d
    		+9.3%
    Mar 26
    Reported May 5
    		$0.87$0.76$0.69 - $0.82+14.47%Beat10
    1
    2
    30d
    		+40.3%
    Dec 25
    Reported Feb 10
    		$0.94$0.81$0.38 - $1.02+16.05%Beat13
    6
    1
    30d
    		+70.9%
    Sep 25
    Reported Nov 4
    		$0.78$0.67$0.53 - $0.71+16.42%Beat13
    1
    1
    30d
    		+66.0%
    Jun 25
    Reported Jul 28
    		$0.75$0.65$0.52 - $0.72+15.38%Beat12
    4
    1
    30d
    		-10.7%
    Mar 25
    Reported May 13
    		$0.62$0.37$0.34 - $0.55+69.12%Beat11
    3
    0
    30d
    		+264.7%
    Dec 24
    Reported Feb 11
    		$0.55$0.49$0.24 - $0.63+12.24%Beat14
    5
    2
    30d
    		+66.7%
    Sep 24
    Reported Oct 29
    		$0.47$0.42$0.38 - $0.44+11.90%Beat13
    4
    1
    30d
    		+370.0%
    Jun 24
    Reported Aug 6
    		$0.84$0.37$0.30 - $0.43+127.03%Beat15
    5
    1
    30d
    		+171.0%
    Mar 24
    Reported Apr 30
    		$0.17$0.29$0.11 - $0.47-41.38%Miss15
    4
    1
    30d
    		+6.3%
    Dec 23
    Reported Feb 6
    		$0.33$0.31$0.15 - $0.38+6.45%Beat13
    7
    3
    30d
    		+1200.0%

    Key Metrics

    Valuation
    P/E Ratio19.99EV/EBITDA17.17x
    Price/FCF14.88xFCF Yield6.72%
    Profitability
    Profit Margin35.40%Operating Margin40.70%
    ROE44.30%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio3.46xQuick Ratio3.38x
    Trading Statistics
    Beta0.42Avg Volume2.73M
    52-Week High$73.6952-Week Low$39.71

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$68.58
    SMA 20$65.63
    SMA 50$60.92
    SMA 200$51.57
    EMA 10$68.63
    EMA 20$66.25
    EMA 50$62.05
    EMA 200$53.52

    MACD

    Line: 2.98Signal: 2.66Hist: 0.32

    ADX

    ADX: 41.5+DI: 29.5-DI: 14.4

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down8.0
    PSAR$73.69

    Bollinger Bands

    Upper Band$73.32
    Lower Band$57.95
    %B Position2342%(Upper)
    Band Width0.76

    RSI (14-Day)

    Neutral
    66.0

    Momentum Oscillators

    Stoch %K71.6
    Stoch %D80.8
    Williams %R-38.0
    ROC (10d)7.8%
    Momentum5.04
    CCI (20d)79.0
    MFI (14d)74.7

    Volatility Measures

    ATR (14d)$2.29(3.3%)
    StdDev (20d)3.84
    Hist Vol33.6%(Moderate)

    Volume Flow

    VWAP$69.30
    OBV14.9M
    AD Line-2.8M
    CMF (20d)0.089

    Volume Metrics

    Avg Vol (20d)2.7M
    Vol Ratio0.7x
    VWMA (20d)$66.32

    Pivot Points

    R3$77.34
    R2$75.52
    R1$72.11
    Pivot Point$70.29
    S1$66.88
    S2$65.06
    S3$61.65

    Advanced Oscillators

    TSI48.04
    Ultimate Osc47.9
    KST155.72

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$628.69M$610.81M$598.66M$597.75M$568.26M$555.45M$566.75M$539.54M$637.18M$425.23M$479.65M$471.92M
    Cost of Revenue$20.66M$19.95M$26.48M$18.57M$19.47M$19.17M$19.96M$17.33M$17.67M$21.26M$21.75M$18.77M
    Gross Profit$608.03M$590.86M$572.18M$579.18M$548.79M$536.27M$546.79M$522.21M$619.51M$403.97M$457.90M$453.15M
    Operating Expenses$359.62M$339.52M$336.97M$342.64M$335.21M$349.42M$383.58M$386.14M$343.64M$374.51M$376.11M$470.73M
    R&D$211.99M$199.92M$213.25M$199.16M$200.36M$212.23M$249.00M$222.57M$211.15M$227.69M$244.67M$332.58M
    SG&A$147.63M$139.60M$123.02M$123.66M$134.86M$137.18M$134.33M$111.80M$132.01M$113.98M$131.44M$138.14M
    Operating Income$248.41M$251.34M$235.22M$236.54M$213.58M$186.86M$163.21M$136.07M$275.87M$29.46M$81.79M$-17,583,000
    Interest Income$14.21M$16.13M$17.43M$15.92M$16.79M$19.08M$21.30M$18.71M$17.26M$19.89M$21.39M$23.11M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$262.68M$267.69M$252.69M$252.41M$230.41M$205.69M$184.77M$154.75M$292.85M$49.27M$103.04M$5.82M
    Income Tax Expense$50.63M$57.22M$8.16M$58.84M$45.57M$46.07M$44.91M$36.78M$66.73M$11.95M$17.52M$4.78M
    Net Income$212.05M$210.47M$244.53M$193.58M$184.85M$159.62M$139.86M$117.97M$226.12M$37.32M$85.52M$1.04M
    EBITDA$255.45M$258.51M$242.21M$243.91M$220.97M$193.96M$171.12M$143.50M$282.92M$35.75M$88.18M$-10,998,000
    EBIT$248.47M$251.56M$235.26M$236.49M$213.63M$186.61M$163.48M$136.05M$275.59M$29.37M$81.65M$-17,294,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EXEL

    News

    Handa Pharmaceuticals' First Three Quarters Profit Falls Over 70%; Originator Files New Patent Infringement Suit, Shares Hit Limit Down

    Handa Pharmaceuticals reported a substantial decline in net profit and earnings per share for the first three quarters of 2026...

    BigGo Finance•11/5/26•Somewhat-Bullish

    Exelixis Inc stock hits all-time high at 73.49 USD

    Exelixis Inc (EXEL) stock reached an all-time high of $73.49, trading just 1% below its 52-week peak, reflecting strong investor confidence and a 79.12% surge over the past year. The biotechnology company reported robust...

    Investing.com•11/5/26•Bullish

    What Was Exelixis Telling You Before Its Stock Ran?

    Exelixis (EXEL) saw its stock return 76.0% between October 2025 and October 2026, significantly outperforming the S&P 500. This surge followed the FDA's acceptance of its experimental cancer drug, zanzalintinib...

    Trefis•11/1/26•Bullish

    Exelixis, Inc. Stock 12‑Month Price Target Raised to $59.69, Implies 10% Downside

    The average 12-month price target for Exelixis, Inc. stock has increased to $59.69 from $55.5, based on estimates from 13 analysts. This updated target suggests a potential 10% downside from the October 29 closing price....

    TradingView•10/31/26•Somewhat-Bearish

    Exelixis, Inc. Stock 12‑Month Price Target Raised to $59.21, Implies 11% Downside

    Exelixis, Inc. (EXEL) has seen its average 12-month price target raised to $59.21 by 14 analysts, with forecasts ranging from $41 to $76 per share. This updated target suggests an 11% potential downside from the October...

    TradingView•10/30/26•Somewhat-Bearish

    EXEL Valuation and Fair Value

    P/E
    20.0x
    Forward P/E
    17.1x
    EV/EBITDA
    17.2x
    P/FCF
    14.9x
    PEG
    2.6x
    P/B
    9.5x
    See GNG's fair value

    EXEL Profitability: Margins, ROIC and FCF

    Gross margin
    96.5%
    Operating margin
    40.7%
    Net margin
    35.4%
    ROE
    44.3%
    FCF yield
    6.7%

    EXEL Competitors

    CompanyTicker
    Revvity Inc.RVTY
    Neurocrine Biosciences IncNBIX
    Ascendis Pharma ASASND
    ICON PLCICLR
    Hologic IncHOLX
    Charles River LaboratoriesCRL
    Medpace Holdings IncMEDP
    Solventum Corp.SOLV

    Sector: Healthcare

    EXEL Analyst Ratings

    Consensus
    Hold
    Analysts
    17
    Strong Buy
    1
    Buy
    5
    Hold
    10
    Sell
    0
    Strong Sell
    1

    EXEL Bull Case vs Bear Case

    Bull case

    • EXEL has a 35.4% net profit margin.
    • EXEL beat EPS estimates in 100.0% of its last 8 reported quarters.
    • EXEL grew quarterly revenue 10.2% year over year.

    EXEL Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    20.1%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $1.22

    EXEL Earnings Date

    EXEL reports Feb 8, 2027, after the close. The date is estimated.

    EXEL Earnings Call

    The latest EXEL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    EXEL ETF Holders

    GNG tracks 25 ETFs that hold EXEL. The largest weights:

    1. Invesco S&P MidCap Quality ETF (XMHQ), 3.56% of the fund
    2. Fundstrat Granny Shots US Small & Mid-Cap ETF (GRNJ), 1.70% of the fund
    3. State Street SPDR S&P Biotech ETF (XBI), 1.63% of the fund
    4. American Century U.S. Quality Growth ETF (QGRO), 1.39% of the fund
    5. ERShares Private-Public Crossover ETF (XOVR), 1.26% of the fund
    Open the ETF Stock Exposure tool for EXEL

    See insider activity

    Frequently Asked Questions About EXEL

    When does EXEL report earnings?

    Exelixis Inc (EXEL) is expected to report earnings on Feb 8, 2027.

    Does EXEL pay dividends?

    Exelixis Inc (EXEL) does not currently pay a regular dividend.

    What is EXEL's P/E ratio?

    Exelixis Inc has a price-to-earnings (P/E) ratio of 19.99.

    What is EXEL's market cap?

    Exelixis Inc (EXEL) has a market capitalization of $16.77B with a current stock price of $69.57.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In